4
Changes in Ownership
Entrada Therapeutics, Inc. Filed Acc 0001689375-23-000015
Chief Financial Officer sold 1,747 shares at an average $10.53 ($18,389)
- Chief Financial Officer gave up 1,005 shares (to pay taxes)
- Chief Financial Officer acquired 28,400 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| WENTWORTH KORY JAMES Chief Financial Officer | 2023-03-01 | Grant or award | +28,400 | 44,909 | D: show line 1 in the form | ||
| WENTWORTH KORY JAMES Chief Financial Officer | 2023-03-02 | Shares withheld for taxes | −1,005 | $11.60 | $11,654 | 43,904 | D: show line 2 in the form |
| WENTWORTH KORY JAMES Chief Financial Officer | 2023-03-02 | Sale | −1,602 | $10.46 | $16,761 | 42,302 | D: show line 3 in the form |
| WENTWORTH KORY JAMES Chief Financial Officer | 2023-03-02 | Sale | −145 | $11.23 | $1,628 | 42,157 | D: show line 4 in the form |
| Open-market sales · 1,747 sh · avg $10.53 · $18,389 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| WENTWORTH KORY JAMES Chief Financial Officer | 2023-03-01 | Grant or award · Stock Option (Right to Buy) | +43,000 | 43,000 | D: show line 5 in the form |
Loading xslF345X03/wf-form4_167787941368609.xml…